<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021276</url>
  </required_header>
  <id_info>
    <org_study_id>GVHD-001</org_study_id>
    <nct_id>NCT05021276</nct_id>
  </id_info>
  <brief_title>Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD</brief_title>
  <official_title>A Prospective Multicenter, Single-arm Clinical Study of Anti-CD25 Monoclonal Antibody Combined With Ruxolitinib in the Treatment of Grade 3-4 Steroid-resistant Acute Graft-versus-host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Soochow Hopes Hematonosis Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huai'an Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of&#xD;
      allogeneic hematopoietic stem cell transplantation. The recognized first-line treatment for&#xD;
      grade 3-4 aGVHD is systemic glucocorticoid. However, there is no recognized second-line&#xD;
      treatment for grade 3-4 steroid-resistant aGVHD (SR-aGVHD). The investigators try to observe&#xD;
      the efficacy and safety of early application of anti-CD25 monoclonal antibody(basiliximab)&#xD;
      combined with ruxotilinib in the treatment of severe SR-aGVHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adults ages 18-65 with grade 3-4 SR-aGVHD&#xD;
&#xD;
      Design&#xD;
&#xD;
      Participants with grade 3-4 steroid-refractory acute GVHD (progression after 3 days or lack&#xD;
      of improvement after 5 days of 1.5-2 mg/kg/d systemic steroids) receive combined therapy of&#xD;
      basiliximab and ruxolitinib.&#xD;
&#xD;
      Basiliximab is given 20mg twice a week for week 1, and then once a week until GVHD of the&#xD;
      participants reaches grade 1(3 episodes for minimum).&#xD;
&#xD;
      Ruxolitinib is given 5mg twice a day for one day and then escalates to 10mg twice a day if&#xD;
      the participant is not administered with triazole antifungal agent.&#xD;
&#xD;
      The drug dose will be adjusted according to participants' clinical manifestations, blood cell&#xD;
      count, infection status and so on.&#xD;
&#xD;
      For participants with lower gastrointestinal GVHD, intravenous cyclosporine or tacrolimus is&#xD;
      given and plasma concentration is monitored in a safe and effective range.&#xD;
&#xD;
      Best supportive treatment is given, including broad-spectrum anti-infection, nutrition&#xD;
      support, and blood transfusion.&#xD;
&#xD;
      The investigators access the efficacy and safety of second-line therapy once a week from day&#xD;
      14 until complete remission is received. Then the investigators access the hematological&#xD;
      disease status, aGVHD, cGVHD, infection state once a month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate at day 28</measure>
    <time_frame>day 28</time_frame>
    <description>The primary endpoint is the overall response rate (ORR) at day 28 defined as proportion of patients demonstrating partial (PR) or complete response (CR) without requirement for additional systemic immunosuppressive therapy (IST) at day 28 after second-line treatment initiates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR at d14/d56</measure>
    <time_frame>day 14, day 56</time_frame>
    <description>overall response rate at day 14/56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>through study completion(median 12 days according to previous study)</time_frame>
    <description>Time to response, defined as time from the day treatment initiates to the date of first documentation PR or CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>through study completion, an average of 1year</time_frame>
    <description>Duration of response, assessed for responders only by calculating the time from first response to the date of first observation of aGvHD relapse/progression or the date of additional IST for GvHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>through study completion, an average of 1year</time_frame>
    <description>Overall survival (OS) defined as time from the day treatment initiates to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS</measure>
    <time_frame>through study completion, an average of 1year</time_frame>
    <description>Event-free survival (EFS) defined as the time from the day treatment initiates to the date of recurrence of underlying hematologic disease, graft failure or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence rate of secondary grade 3-4 liver aGVHD</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>incidence rate of secondary grade 3-4 liver aGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence rated of chronic GVHD</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>incidence rated of chronic GVHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Safety and Efficacy</condition>
  <arm_group>
    <arm_group_label>ruxolitinib+basiliximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with grade 3-4 steroid-refractory aGVHD receive combined therapy of basiliximab and ruxolitinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib and basiliximab are both second-line treatment for grade 3-4 steroid-resistant acute graft-versus-host disease.</description>
    <arm_group_label>ruxolitinib+basiliximab</arm_group_label>
    <other_name>basiliximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of primary grade 3-4(according to MAGIC criteria) steroid-resistant&#xD;
             acute graft-versus-host disease(progression after 3 days or lack of improvement after&#xD;
             5 days of systemic 1.5-2 mg/kg steroids).&#xD;
&#xD;
          -  Age 18-65.&#xD;
&#xD;
          -  ECOG scoreâ‰¤3.&#xD;
&#xD;
          -  Must be able to understand and willing to participate in the study and sign the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refractory/secondary graft-versus-host disease.&#xD;
&#xD;
          -  Severe complications such as myocardial infarction, chronic cardiac insufficiency,&#xD;
             hepatic failure, renal insufficiency, etc.&#xD;
&#xD;
          -  Clinically uncontrolled active infections.&#xD;
&#xD;
          -  Other Malignant tumors with progression.&#xD;
&#xD;
          -  Ecg: QT interval &gt; 450 ms.&#xD;
&#xD;
          -  Allergic to arsenic agent.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Expected survival &lt;60 days.&#xD;
&#xD;
          -  Undergoing other drug clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuefeng He, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuefeng He, doctor</last_name>
    <phone>86-18914031640</phone>
    <email>hexuefeng@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fei Zhou, doctor</last_name>
    <phone>86-15051425673</phone>
    <email>zhoufei@suda.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuefeng He, doctor</last_name>
      <phone>86-18914031640</phone>
      <email>hexuefeng@suda.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Soochow University</investigator_affiliation>
    <investigator_full_name>Xuefeng He</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

